Showing results (91-100 of 101) with videos related to

Sort By:
Pageof 11
Annals of Neurology|December 23, 2011
Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility lociNikolaos A Patsopoulos, , , et al.
CNS Drugs|April 4, 2026
Preserving Neurological Function in People at High and Low Risk of Aggressive Multiple Sclerosis: An Observational Cohort StudyIzanne Roos, Sifat Sharmin, Serkan Ozakbas, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 21, 2026
Causal effects of multiple sclerosis therapies in left-truncated registry dataDagmawi Chilot Haile, Ibrahima Diouf, Serkan Ozakbas, et al.
Neurology|August 17, 2022
Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple SclerosisIzanne Roos, Charles Malpas, Emmanuelle Leray, et al.
CNS Drugs|September 18, 2021
Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International CohortsSifat Sharmin, Mathilde Lefort, Johanna Balslev Andersen, et al.
Multiple Sclerosis and Related Disorders|June 11, 2021
The effectiveness of natalizumab vs fingolimod-A comparison of international registry studiesJohanna B Andersen, Sifat Sharmin, Mathilde Lefort, et al.
European Journal of Neurology|January 24, 2023
Variability of the response to immunotherapy among subgroups of patients with multiple sclerosisIbrahima Diouf, Charles B Malpas, Sifat Sharmin, et al.
Brain : a Journal of Neurology|June 27, 2023
The risk of secondary progressive multiple sclerosis is geographically determined but modifiableSifat Sharmin, Izanne Roos, Steve Simpson-Yap, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|May 20, 2026
Comparative effectiveness of ocrelizumab in subgroups of patients with multiple sclerosis: a multi-registry observational cohort studyIzanne Roos, Sifat Sharmin, Dana Horakova, et al.
JAMA Neurology|April 14, 2025
Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple SclerosisJannis Müller, Sifat Sharmin, Johannes Lorscheider, et al.
Pageof 11